Abemaciclib Regimens Approved in Japan for Recurrent HR+/HER2- Breast Cancer

September 21, 2018 – The Japanese Ministry of Health, Labor, and Welfare has approved abemaciclib for the treatment of patients with hormone receptor (HR)-positive, HER2-negative unresectable or recurrent breast cancer in combination with fulvestrant or an aromatase inhibitor (AI), according to a statement by Eli Lilly, the manufacturer of the CDK4/6 inhibitor. Additionally, the company received a positive opinion from the European Medicines Agency’s Committee … (leggi tutto)